These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7295078)

  • 21. Middle molecules in uraemia.
    Fürst P; Asaba M; Gordon A; Zimmerman L; Bergström J
    Proc Eur Dial Transplant Assoc; 1975; 11():417-26. PubMed ID: 1105558
    [No Abstract]   [Full Text] [Related]  

  • 22. [Uremic toxins].
    Vanholder R
    Nephrologie; 2003; 24(7):373-6. PubMed ID: 14650749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved separation and quantification of the "middle molecule" b4-2 in uremia.
    Faguer P; Man NK; Cueille G; Di Giulio S; Funck-Brentano JL
    Clin Chem; 1983 Apr; 29(4):703-7. PubMed ID: 6831703
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Time profiles of peritoneal and renal clearances of different uremic solutes in incident peritoneal dialysis patients.
    Bammens B; Evenepoel P; Verbeke K; Vanrenterghem Y
    Am J Kidney Dis; 2005 Sep; 46(3):512-9. PubMed ID: 16129214
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low molecule and middle molecule metabolites with haemodynamic activity in the ultrafiltrate from uraemic patients (author's transl).
    Pogglitsch H; Petek W; Waller J; Stübchen-Kirchner H
    Wien Klin Wochenschr; 1977 Dec; 89(24):812-9. PubMed ID: 595605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Defining peritoneal dialysis adequacy: Kt/Vurea revisited.
    Zhe XW; Shan YS; Cheng L; Tian XK; Wang T
    Ren Fail; 2007; 29(3):347-52. PubMed ID: 17497450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isotachophoretic separation of middle molecule peptides in uremic body fluids.
    Zimmerman L; Baldesten A; Bergström J; Fürst P
    Clin Nephrol; 1980 Apr; 13(4):183-8. PubMed ID: 7379369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Middle molecules as a marker of uremic toxins.
    Wu ZG; Liao LT; Cai ZH; Lu ZN; Cai YD; Sheng PF
    Adv Exp Med Biol; 1987; 223():33-7. PubMed ID: 3447449
    [No Abstract]   [Full Text] [Related]  

  • 30. Uremic neuropathy: evidence of middle molecule toxicity.
    Milutinovic J; Babb AL; Eschbach JW; Follette WC; Graefe U; Strand MJ; Scribner BH
    Artif Organs; 1978 Feb; 2(1):45-51. PubMed ID: 687020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Is conventional hemodialysis an appropriate dialysis?].
    Andrés E
    Nefrologia; 2005; 25 Suppl 2():10-4. PubMed ID: 16050395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential role of middle molecular compounds in the development of uremic anemia.
    Leber HW; Debus E; Grulich U; Schütterle G
    Artif Organs; 1981; 4 Suppl():63-7. PubMed ID: 7295098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The effect of hemodialysis and continuous ambulatory peritoneal dialysis on renal anemia].
    Stojimirović B; Grujić-Adanja G
    Srp Arh Celok Lek; 1997; 125(5-6):163-7. PubMed ID: 9265238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Study on the analogy of gel permeation chromatography and cuprophan dialysis for the isolation of uremic 'middle molecules' using model compounds.
    Schoots AC; Cramers CA
    J Chromatogr; 1989 Dec; 497():79-86. PubMed ID: 2625481
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma middle molecules in asymptomatic and "sick" uremic patients.
    Asaba H; Bergström J; Fürst P; Johnson C; Yahiel V
    Artif Organs; 1981; 4 Suppl():137-42. PubMed ID: 7295080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Large-scale isolation of middle and higher molecular weight uremic toxins.
    Brunner H; Mann H; Essers U; Byrne T
    Artif Organs; 1981; 4 Suppl():41-5. PubMed ID: 7295094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Urea kinetic and middle molecule approaches to assessing the adequacy of hemodialysis and CAPD.
    Keshaviah P
    Kidney Int Suppl; 1993 Feb; 40():S28-38. PubMed ID: 8445836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Renal replacement therapy by hemodialysis: an overview].
    Jacobs C
    Nephrol Ther; 2009 Jul; 5(4):306-12. PubMed ID: 19481513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Middle molecules separation from uraemic serum (author's transl)].
    Dall'aglio P; Buzio C; Gardini GP; Migone L
    Ateneo Parmense Acta Biomed; 1975; 46(5):331-44. PubMed ID: 1236694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A bench to bedside view of uremic toxins.
    Vanholder R; Baurmeister U; Brunet P; Cohen G; Glorieux G; Jankowski J;
    J Am Soc Nephrol; 2008 May; 19(5):863-70. PubMed ID: 18287557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.